Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Researchers have published a retrospective case series examining ocular manifestations of Lyme disease – a condition ...
Belfast Live on MSN
'I'm living with sight loss and it's an emotional rollercoaster'
His devastating diagnosis came after a routine eye examination and subsequent investigations.
MedPage Today on MSN
Case study: Do these symptoms really indicate a stroke?
Getting to the bottom of the cause in this 29-year-old woman illustrates the diagnostic co ...
Multiple sclerosis (MS) is a chronic disease of the central nervous system. MS disrupts the flow of information between the ...
Oculis Holding AG, a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced that its ...
Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...
Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for its eye disease therapy Privosegtor as a treatment for optic neuritis (ON), ...
Why Oculis Holding (OCS) Is Up 15.3% After FDA Breakthrough Status For Privosegtor In Optic Neuritis
Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and ...
Immune cells (killer T cells) present in the spinal fluid are attacking the Epstein-Barr virus (EBV) in multiple sclerosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results